- NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
- NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
- NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
- NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
- NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
- NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
- NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
- NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
- NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
- NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
More ▼
Key statistics
On Friday, NovaBay Pharmaceuticals Inc (NBY:ASQ) closed at 0.1186, 82.46% above the 52 week low of 0.065 set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.150 |
---|---|
High | 0.2594 |
Low | 0.1048 |
Bid | 0.113 |
Offer | 0.114 |
Previous close | 0.12 |
Average volume | 20.38m |
---|---|
Shares outstanding | 37.83m |
Free float | 37.82m |
P/E (TTM) | -- |
Market cap | 4.49m USD |
EPS (TTM) | -3.11 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:10 BST.
More ▼